Next Article in Journal
Use of Circulating Tumour DNA (ctDNA) for Measurement of Therapy Predictive Biomarkers in Patients with Cancer
Previous Article in Journal
Prevalence of Chronic Kidney Disease and Variation of Its Risk Factors by the Regions in Okayama Prefecture
Previous Article in Special Issue
Therapeutic Interaction of Apatinib and Chidamide in T-Cell Acute Lymphoblastic Leukemia through Interference with Mitochondria Associated Biogenesis and Intrinsic Apoptosis
Review

Harnessing Synthetic Lethal Interactions for Personalized Medicine

by 1,2,3,4
1
Institute of Statistical Science, Academia Sinica, Taipei 115, Taiwan
2
Bioinformatics Program, Taiwan International Graduate Program, Academia Sinica, Taipei 115, Taiwan
3
Genome and Systems Biology Degree Program, Academia Sinica, National Taiwan University, Taipei 115, Taiwan
4
Data Science Degree Program, Academia Sinica, National Taiwan University, Taipei 115, Taiwan
Academic Editors: Giorgio Malpeli and Maria Bencivenga
J. Pers. Med. 2022, 12(1), 98; https://doi.org/10.3390/jpm12010098
Received: 12 December 2021 / Revised: 7 January 2022 / Accepted: 9 January 2022 / Published: 12 January 2022
(This article belongs to the Special Issue Advances in Synthetic Lethality for Personalized Cancer Treatments)
Two genes are said to have synthetic lethal (SL) interactions if the simultaneous mutations in a cell lead to lethality, but each individual mutation does not. Targeting SL partners of mutated cancer genes can kill cancer cells but leave normal cells intact. The applicability of translating this concept into clinics has been demonstrated by three drugs that have been approved by the FDA to target PARP for tumors bearing mutations in BRCA1/2. This article reviews applications of the SL concept to translational cancer medicine over the past five years. Topics are (1) exploiting the SL concept for drug combinations to circumvent tumor resistance, (2) using synthetic lethality to identify prognostic and predictive biomarkers, (3) applying SL interactions to stratify patients for targeted and immunotherapy, and (4) discussions on challenges and future directions. View Full-Text
Keywords: biomarker; cancer; genetic interaction; precision medicine; synthetic lethal biomarker; cancer; genetic interaction; precision medicine; synthetic lethal
Show Figures

Figure 1

MDPI and ACS Style

Shieh, G.S. Harnessing Synthetic Lethal Interactions for Personalized Medicine. J. Pers. Med. 2022, 12, 98. https://doi.org/10.3390/jpm12010098

AMA Style

Shieh GS. Harnessing Synthetic Lethal Interactions for Personalized Medicine. Journal of Personalized Medicine. 2022; 12(1):98. https://doi.org/10.3390/jpm12010098

Chicago/Turabian Style

Shieh, Grace S. 2022. "Harnessing Synthetic Lethal Interactions for Personalized Medicine" Journal of Personalized Medicine 12, no. 1: 98. https://doi.org/10.3390/jpm12010098

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop